UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 6, 2005 (September 30, 2005)
Momenta Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
000-50797 |
|
04-3561634 |
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification |
|
|
|
|
|
675 West Kendall Street, Cambridge, MA |
|
02142 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
(617) 491-9700
(Registrants telephone
number,
including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On September 30, 2005, the Compensation Committee (the Committee) of the Board of Directors of Momenta Pharmaceuticals, Inc. (the Company) approved discretionary cash bonuses to the following executive officers of the Company and in the amounts set forth below:
Executive Officer |
|
Bonus Amount |
|
|
|
|
|
|
|
John Bishop, Vice President, Pharmaceutical |
|
$ |
25,000 |
|
Steven B. Brugger, Senior Vice President, |
|
$ |
25,000 |
|
Ganesh Venkataraman, Senior Vice |
|
$ |
25,000 |
|
Susan K. Whoriskey, Vice President, |
|
$ |
2,000 |
|
The cash bonuses described in this Item 1.01 were approved by the Committee in furtherance of the compensation policies established for the Companys executive officers as set forth in the Executive Officer Compensation Summary filed as Exhibit 10.48 to the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2004. Each of the bonuses were awarded after assessment by the Committee of corporate and individual performances related to the preparation and filing of the Companys abbreviated new drug application.
Item 9.01. Financial Statements and Exhibits.
(c) Executive Officer Compensation Summary (filed as Exhibit 10.48 to the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2004, Commission File No. 0-50797) is incorporated herein by reference.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MOMENTA PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
Date: October 6, 2005 |
By: |
/s/ Richard P. Shea |
|
|
Richard P. Shea |
|
|
Chief Financial Officer |
|
|
(Principal Financial Officer) |
3